Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Retroviral replicating vectors for cancer-targeted gene therapy and immunotherapy

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.04.16
Views: 1772

Dr Noriyuki Kasahara - Miami University School of Medicine, Miami, USA

Dr Noriyuki Kasahara speaks with ecancertv at AACR2016 about his cancer-targeting retroviral therapies which illicit host immune responses.

Historically, oncolytic viruses have struggled to compete with host immunity to reach their target and the immunosuppresive tumour environment. But by using a retroviral factor, Dr Kasahara's lab reports selective targeting of cancer cells with a gene primer that in turn responds to a non-toxic pro-drug to kill the 'infected' tumour cells.

Dr Kasahara reports significant extension to patient survival compared to current chemotherapy treatments, with no systemic toxicity and high-tumour specificity.

Trials are ongoing.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation